Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 6,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Part 1 Clear all
Recruiting Phase 2Phase 3 Interventional

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685
View directory record Official record
Conditions
Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
Interventions
Elenestinib, Placebo
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 11, 2026, 4:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults

NCT04147715
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-648414, Placebo, Midazolam, Dolutegravir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 11, 2026, 4:03 PM EST
Completed Phase 1 Interventional

Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Implantation

NCT04327635
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
PEP
Drug
Lead sponsor
Christopher J. McLeod
Other
Eligibility
21 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 11, 2026, 4:03 PM EST
Completed Phase 2 Interventional Results available

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

NCT02665143
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
Nintedanib and AML induction
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
New Haven, Connecticut • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Nov 11, 2026, 4:03 PM EST
Not yet recruiting Phase 1 Interventional

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

NCT07650357
View directory record Official record
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Interventions
CLSP-5282
Drug
Lead sponsor
Clasp Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 11, 2026, 4:03 PM EST
Recruiting Not applicable Interventional

Evaluating a One-Year Version of the Parent-Child Assistance Program

NCT06163651
View directory record Official record
Conditions
Alcohol Use Disorder, Substance Use Disorders, Alcohol Use Complicating Pregnancy, Unspecified Trimester, Drug Use Disorders, Drug Use Complicating Pregnancy, Unspecified Trimester
Interventions
Parent-Child Assistance Program - One-Year Version
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Enid, Oklahoma • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Nov 11, 2026, 4:03 PM EST
Terminated Phase 1 Interventional

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

NCT06599502
View directory record Official record
Conditions
Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Interventions
AZD0022, Cetuximab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Duarte, California • New York, New York • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 11, 2026, 4:03 PM EST
Recruiting Phase 1 Interventional

Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain

NCT07197645
View directory record Official record
Conditions
Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer
Interventions
153Sm-DOTMP
Drug
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 11, 2026, 4:03 PM EST
Recruiting Not applicable Interventional

Biomarkers to Predict Rotator Cuff Repair Healing on Postoperative MRI

NCT07781553
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
MRN
Diagnostic Test
Lead sponsor
Joseph W. Galvin
Other
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 11, 2026, 4:03 PM EST
Completed Phase 2Phase 3 Interventional Results available

An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

NCT04145531
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia
Interventions
IM JZP-458, IV JZP-458
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 11, 2026, 4:03 PM EST
Terminated Not applicable Interventional Results available

Assessment of Medication Optimization in Rural Kentucky Appalachian Patients With Mild Cognitive Impairment or Dementia

NCT05078437
View directory record Official record
Conditions
Dementia, Mild Cognitive Impairment
Interventions
Medication therapy management
Behavioral
Lead sponsor
Daniela Moga
Other
Eligibility
60 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Nov 11, 2026, 4:03 PM EST
Completed Not applicable Interventional

Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer

NCT00499395
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
positron emission tomography, radiofrequency ablation
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Nov 11, 2026, 4:03 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

NCT02753595
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Nov 11, 2026, 4:03 PM EST
Completed Phase 3 Interventional

Workplace-Sponsored Diet and Exercise Program to Reduce Obesity

NCT00123526
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases, Heart Diseases
Interventions
Diet, Physical Activity
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Nov 11, 2026, 4:03 PM EST
Completed No phase listed Observational

Plaque Inflammation and Dysfunctional HDL in AIM-HIGH

NCT00880178
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Simvastatin and Extended-Release niacin, Simvastatin
Drug
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Nov 11, 2026, 4:03 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Development of Adaptive Deep Brain Stimulation for OCD (Phase 1a)

NCT03457675
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Activa PC+S DBS implant for OCD, One Month Blinded Discontinuation Period
Device · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Providence, Rhode Island • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 11, 2026, 4:03 PM EST
Completed Phase 2 Interventional Results available

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

NCT02776735
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Sarilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Nov 11, 2026, 4:03 PM EST
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

NCT07160725
View directory record Official record
Conditions
Solid Tumours
Interventions
BMS-986517, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Irvine, California • Los Angeles, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 11, 2026, 4:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

NCT05109390
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Cyclosporine, Tacrolimus, Calcium Carbonate, Aluminum/Magnesium Hydroxide/Simethicone, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Nov 11, 2026, 4:03 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

NCT04444050
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986331, Placebo, Matching BMS-986331
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Nov 11, 2026, 4:03 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

NCT05280717
View directory record Official record
Conditions
Covid19
Interventions
sotrovimab
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
10
States / cities
Riverside, California • Atlantis, Florida • Edgewater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 11, 2026, 4:03 PM EST
Terminated Phase 1 Interventional

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

NCT05036291
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
NB004 tablets
Drug
Lead sponsor
Ningbo Newbay Technology Development Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
New Orleans, Louisiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Nov 11, 2026, 4:03 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

NCT07147517
View directory record Official record
Conditions
Respiratory Infection Virus, COVID -19, RSV, FLU
Interventions
Component A0, Component A1, Component A2, Component B
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
2
States / cities
La Jolla, California • San Ysidro, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 11, 2026, 4:03 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effect of (TaVNS) on Anxiety and Brain Function in Distressed Health Care Workers

NCT05132881
View directory record Official record
Conditions
Anxiety, Distress, Emotional, Effects of Vibration, Healthy
Interventions
Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS), Waitlist Control, Healthy Controls: Substudy Group III, Distressed Workers: Subgroup II
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Nov 11, 2026, 4:03 PM EST